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PAR4
NSAID UTILIZATION AMONG COMMERCIALLY 
INSURED MEMBERS IN A MANAGED 
CARE ENVIRONMENT
Hall J, Clouse J,
Ingenix International, Eden Prairie, MN, USA
OBJECTIVE: To evaluate nonsteroidal anti-inflamma-
tory drug (NSAID) utilization among commercially in-
sured members in a managed care environment. METH-
ODS: This was a cross-sectional study of administrative
pharmacy claims data from eleven health plans between
July 1, 1994 and June 30, 1997. Data were used to deter-
mine the prevalence of prescription NSAID use. Analyses
were performed on two groups: those with and those
without a rheumatoid arthritis or osteoarthritis diagnosis
occurring 90 days prior to their first NSAID claim dur-
ing the study period. Members were required to be con-
tinuously enrolled with a drug benefit during the study
period (N  149,216). Acute NSAID utilization (defined
as 3 prescriptions during the study period), chronic
NSAID utilization (defined as 3 NSAID prescriptions
during the study period), and average day supply were
analyzed. RESULTS: The prevalence of NSAID use
among continuously enrolled health plan members of all
ages was 32% during the three-year study period. Among
members with arthritis, 37% were considered acute
NSAID users and 63% were considered chronic users. A
30 to 34 days supply of NSAIDs was most common for
members with arthritis. Among members without arthri-
tis, 71% were considered acute NSAID users and 29%
were considered chronic users. A 10 to 15 day supply
was most common for members without a recent arthritis
diagnosis. CONCLUSION: The majority of NSAID users
in the managed care population used NSAIDs on an
acute basis. Consequently, use of the more costly, new
class of NSAIDS, COX-2 inhibitors, which may reduce
the incidence of gastrointestinal (GI) bleeding among
those at increased risk of GI irritation due to chronic
NSAID exposure, may not be warranted for most NSAID
users.
PAR5
COMPARING THE HEALTH RELATED QUALITY 
OF LIFE OUTCOMES OF TREATMENT FOR 
EARLY RHEUMATOID ARTHRITIS
Bury-Maynard D1, Kosinski M1, Wanke LA2, Buatti MC3
1QualityMetric, Inc., Lincoln, RI, USA; 2Immunex Corporation, 
Seattle, WA, USA; 3Wyeth-Ayerst Laboratories, Philadelphia, 
PA, USA
Health related quality of life (HQL) measures provide
benchmarks by which to judge the effectiveness of treat-
ment that might otherwise be lost by relying on labora-
tory measures. OBJECTIVE: To compare the impact of 3
treatments for early RA (3 years) on HQL. METH-
ODS: The SF-36 Health Survey (SF-36) and the Health
Assessment Questionnaire (HAQ) were self-administered
by 632 patients participating in a double-blind, random-
ized, controlled clinical trial of three treatments (etaner-
cept 25 mg and 10 mg and methotrexate) for early RA.
Patients were followed over the course of one year with 9
interim follow-up assessments. RESULTS: Treatment
had its greatest impact on measures of physical health
status, specifically the SF-36 physical (PCS) and HAQ
summary scales. To a lesser degree treatment also im-
proved mental health status as determined by the SF-36
mental (MCS) summary scale. Patients in the etanercept
25 mg and MTX groups improved by as much as a stan-
dard deviation on both PCS (10 points) and HAQ (1 point)
summary scales by week 52. Patients in the etanercept 10
mg group improved by nearly a standard deviation on
the HAQ (0.8 points) summary scale but only 1/2 of a
standard deviation on the PCS (5 points) scale by week
52. Average improvements in PCS and HAQ scores during
early follow-up (2- and 4-week) assessments for patients
receiving etanercept 25 mg were more than two times the
amount observed for patients receiving MTX (P 
0.001). CONCLUSION: A higher dose of Etanercept
achieved a quicker improvement of functioning and well
being that was maintained over the course of the year.
PAR6
QUALITY OF LIFE MEASUREMENTS AS 
PREDICTORS OF CHANGE IN THERAPY 
IN PATIENTS WITH 
MUSCULOSKELETAL DISORDERS
Yazdani C1, Cox ER2, Castro WLR3
1NDC Health Information Services, Phoenix, AZ, USA; 2School 
of Pharmacy, University of Arizona, Tucson, AZ, USA; 3School 
of Medicine, University of Arizona, Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to evaluate
the association between self-rating of physical and men-
tal health and changes in prescription therapy in the
course of the office visit in the treatment of patients with
musculoskeletal disorders. METHODS: Patients visiting
one of the two outpatient clinics in Tucson, Arizona with
arthritic symptoms as their chief complaint were invited
to complete a self-administered questionnaire. In addi-
tion to demographics and diagnoses information, data
was collected on medication profile, scores on a func-
tional status instrument (Health Assessment Question-
naire), and quality of life instruments (Feeling Thermom-
eter; 12-item Short Form Health Survey). The data were
collected between March and May 1998. RESULTS:
Among 772 patients, 112 (14.5%) received additional
medication following the visit, 29 (3.8%) had a medica-
tion discontinued, and 51 (6.6%) experienced both an
addition and a discontinuation of medication. According
to univariate statistics, patients who received additional
medication reported more functional limitation (P 
0.05) and poorer overall health (SF-12 Physical, P 
0.001; SF-12 Mental, P  0.005; FT, P  0.05), com-
pared to patients whose therapy remained unchanged.
After adjusting for age, gender, comorbid condition, spe-
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cific diagnosis and pre-visit medication use, the associa-
tion between quality of life measurements and change in
therapy was no longer significant. CONCLUSION: Pa-
tients with musculoskeletal disorders who perceive their
mental and physical health as poor and report greater
levels of functional limitations are more likely to receive
an additional medication during a medical encounter.
Since therapy change is also a function of specific patient
diagnosis, future analyses should evaluate self-rating
health scores and therapy change within patients with
specific diagnosis.
PAR7
THE LONGTERM SAFETY AND EFFECTIVENESS 
OF CYCLOSPORINE IN PATIENTS WITH SEVERE 
RHEUMATOID ARTHRITIS (RA)
Marra CA1, Guh D1, Fisher JH2, Chalmers A2, Esdaile J2, Anis AH1
1CHEOS, St. Paul’s Hospital, Vancouver, BC, Canada; 2 Mary 
Pack Arthritis Centre, Vancouver, BC, Canada
Patient registries go beyond clinical trials with respect to
the assessment of long-term outcomes and measures of
effectiveness. OBJECTIVES: To assess the long-term
safety and effectiveness of cyclosporine (CyA) in a popu-
lation with severe RA. METHODS: All RA patients in
British Columbia treated with CyA between 1991 and
1997 were registered. Demographics and RA treatments
were prospectively collected. Joint count [JC], morning
stiffness [MS], fatigue duration and toxicity parameters
(systolic and diastolic blood pressure [SBP and DBP], and
serum creatinine [SCr]) were assessed monthly up to 84
months. Baseline and serial data were compared using
paired tests. Survival analysis was used to assess time to
CyA discontinuation. RESULTS: 133 severe RA patients
[100 (75%) female, median age 58 years (28–82), median
RA duration 13.5 years (2–54), 98% previous DMARD]
were evaluated. CyA treatment data included duration
(median 14 months, 2–84), dose changes (median 8,
3–42), and dose at cessation (mean 3.25 mg/kg/day, 1.2–
4.5). 27 (25%) received concomitant methotrexate ther-
apy. CyA discontinuation occurred in 37 (28%) patients
due to ineffectiveness (29) and toxicity (8). Significant re-
ductions occurred in JC up to 24 months (32%, 41%,
and 54% at 6, 12, and 24 months respectively; all P 
0.001), and in fatigue duration (55% and 71% at 24 and
36 months respectively; P  0.019 and 0.009). SBP,
DBP, and SCr were significantly elevated over baseline
values throughout treatment. Discontinuation followed a
bimodal pattern with most occurring between 10 and 20
months and a slower rate thereafter. CONCLUSIONS:
Longterm treatment with CyA appears to be effective for
severe RA however SBP, DBP and SCr are adversely af-
fected in most patients.
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THE NEED FOR A QUALITY-OF-LIFE 
INSTRUMENT FOR ERECTILE DYSFUNCTION: 
A SYSTEMATIC REVIEW OF THE LITERATURE
Lenderking WR1,2, Sweeney SL2, Pashos CL1,2, Flanders SC3
1Abt Associates Clinical Trails, Cambridge, MA, USA; 2Harvard 
Medical School, Boston, MA, USA; 3TAP Holdings Inc., 
Deerfield, IL, USA
OBJECTIVES: To determine the state-of-the-art in qual-
ity-of-life assessment associated with male sexual func-
tioning/erectile dysfunction. METHODS: Using Medline,
we identified assessment instruments and scales by search-
ing the keywords: “erectile dysfunction,” “impotence,”
“quality of life,” and “sexual dysfunction.” We focused
on scales published since 1980 in English with evidence
of validity and reliability. We then evaluated these scales
regarding their primary use, operationalization of do-
mains, and psychometric properties. RESULTS: We in-
cluded 19 instruments designed to measure aspects of
male sexual functioning. Instruments were classified by
their primary use into symptom measures (11), quality-
of-life measures (3), couple assessments (4-one of these
was also counted as a symptom measure), treatment sat-
isfaction questionnaires (1), and diagnostic tools (1).
Most measured the domains of sex drive, erection, and
orgasm, using different terms and approaches. Addition-
ally, the domains varied in how they were operational-
ized, with some instruments assessing frequency and
others measuring intensity. Psychometric data revealed
varying degrees of methodological sophistication. CON-
CLUSIONS: There are a variety of scales available for
the assessment of male sexual functioning and erectile
dysfunction. However, the development of these mea-
sures has been ad hoc, with relatively little uniformity in
terms of which domains are measured and how common
domains are operationalized. Most questionnaires are
symptom measures, which do not measure the conse-
quences of erectile dysfunction on quality of life. Conse-
quently, a new instrument to explicitly assess domains of
quality of life associated with erectile dysfunction, in ad-
dition to symptoms, would be a valued addition to the
literature in support of clinical practice and research.
PMW2
DOES TESTOSTERONE AFFECT 
HEALTH-RELATED QUALITY OF LIFE IN 
HEALTHY, ELDERLY MALES?—A PILOT STUDY
Reddy P1, White CM1, Dunn AB2, Moyna NM3, 
Thompson PD3
1Pharmacy School, University of Connecticut, Storrs, CT, USA; 
2Pharmacy School, Northeastern University, Boston, MA, USA; 
3Cardiology Department, Hartford Hospital, Hartford, CT, USA
